Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia

Du,Xin; Tong,Jia; Lu,Hongying; He,Cong; Du,Shenghong; Jia,Peimin; Zhao,Weili; Xu,Hanzhang; Li,Junmin; Shen,Zhixiang; Wu,Yingli; Tong,Jianhua; Zhou,Li

doi:10.3892/mmr.2017.6554

Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia

Authors:
- Xin Du
- Jia Tong
- Hongying Lu
- Cong He
- Shenghong Du
- Peimin Jia
- Weili Zhao
- Hanzhang Xu
- Junmin Li
- Zhixiang Shen
- Yingli Wu
- Jianhua Tong
- Li Zhou
View Affiliations

Affiliations: State Key Laboratory of Medical Genomics, Department of Hematology, Faculty of Medical Laboratory Science, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China, Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Department of Pathophysiology, Chemical Biology Division of Shanghai Universities E‑Institutes, Key Laboratory of Cell Differentiation and Apoptosis of The Chinese Ministry of Education, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China
Published online on: May 9, 2017 https://doi.org/10.3892/mmr.2017.6554
Pages: 101-108
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite advances in the treatment of T‑cell acute lymphoblastic leukemia (T‑ALL), the outcome of T‑ALL treatment remains unsatisfactory, therefore, more effective treatment is urgently required. The present study examined the cytotoxicities of bortezomib in combination with daunorubicin against human Jurkat and Molt‑4 T‑ALL cells and primary T‑ALL cells. Compared with treatment alone, co‑exposure of cells to bortezomib and daunorubicin resulted in a significant increase in cell death in the Jurkat cells, as evidenced by the increased percentage of Annexin V‑positive cells, the formation of apoptotic bodies. In addition, the administration sequence of bortezomib and daunorubicin had an effect on cell viability. Treatment with bortezomib followed by daunorubicin treatment was more effective, compared with treatment with daunorubicin followed by bortezomib. Co-treatment with bortezomib and daunorubicin markedly enhanced the activation of caspase‑3, ‑8 and ‑9, which was reversed by the pan‑caspase inhibitor, Z‑VAD‑FMK. In addition, cotreatment with bortezomib and daunorubicin enhanced the collapse of mitochondrial transmembrane potential and upregulated the proapoptotic protein, B‑cell lymphoma 2 (Bcl‑2)‑interacting mediator of cell death (Bim), but not Bcl‑2 or Bcl‑extra large. Consistent with this, it was demonstrated that cotreatment of bortezomib and daunorubicin efficiently induced apoptosis in primary T‑ALL cells, and cell death was associated with the collapse of mitochondrial transmembrane potential and the upregulation of Bim. Taken together, these findings indicated that the combination of bortezomib and daunorubicin significantly enhanced their apoptosis‑inducing effect in T‑ALL cells, which may warrant further investigation in preclinical and clinical investigations.

View Figures

View References

1	Pui CH, Robison LL and Look AT: Acute lymphoblastic leukaemia. Lancet. 371:1030–1043. 2008. View Article : Google Scholar : PubMed/NCBI
2	Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de Thé H, El-Sabban ME and Hermine O: New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 5:664–672. 2004. View Article : Google Scholar : PubMed/NCBI
3	Marks DI and Rowntree C: Management of adults with T-cell lymphoblastic leukemia. Blood. 129:1134–1142. 2017. View Article : Google Scholar : PubMed/NCBI
4	Johnson DE: The ubiquitin-proteasome system: Opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer. 22:T1–T17. 2015. View Article : Google Scholar : PubMed/NCBI
5	Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE and Cheung MC: Bortezomib in multiple myeloma: Systematic review and clinical considerations. Curr Oncol. 21:e573–e603. 2014. View Article : Google Scholar : PubMed/NCBI
6	Orlowski RZ and Kuhn DJ: Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res. 14:1649–1657. 2008. View Article : Google Scholar : PubMed/NCBI
7	Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M and Blaney SM: A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A children's oncology group study. Clin Cancer Res. 13:1516–1522. 2007. View Article : Google Scholar : PubMed/NCBI
8	Bertaina A, Vinti L, Strocchio L, Gaspari S, Caruso R, Algeri M, Coletti V, Gurnari C, Romano M, Cefalo MG, et al: The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 176:629–636. 2017. View Article : Google Scholar : PubMed/NCBI
9	Howard DS, Liesveld J, Phillips GL II, Hayslip J, Weiss H, Jordan CT and Guzman ML: A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leuk Res. 37:1502–1508. 2013. View Article : Google Scholar : PubMed/NCBI
10	Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J and Bostrom BC: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium: Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study. Blood. 120:285–290. 2012. View Article : Google Scholar : PubMed/NCBI
11	Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, et al: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 361:1235–1248. 2009. View Article : Google Scholar : PubMed/NCBI
12	Pommier Y, Leo E, Zhang H and Marchand C: DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 17:421–433. 2010. View Article : Google Scholar : PubMed/NCBI
13	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
14	Crawford LJ and Irvine AE: Targeting the ubiquitin proteasome system in haematological malignancies. Blood Rev. 27:297–304. 2013. View Article : Google Scholar : PubMed/NCBI
15	Soligo D, Servida F, Delia D, Fontanella E, Lamorte G, Caneva L, Fumiatti R and Lambertenghi Deliliers G: The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol. 113:126–135. 2001. View Article : Google Scholar : PubMed/NCBI
16	Du XL and Chen Q: Recent advancements of bortezomib in acute lymphocytic leukemia treatment. Acta Haematol. 129:207–214. 2013. View Article : Google Scholar : PubMed/NCBI
17	Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P and Grant S: Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. Br J Haematol. 153:222–235. 2011. View Article : Google Scholar : PubMed/NCBI
18	Lieu C, Chow L, Pierson AS, Eckhardt SG, O'Bryant CL, Morrow M, Tran ZV, Wright JJ and Gore L: A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 27:53–62. 2009. View Article : Google Scholar : PubMed/NCBI
19	Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G and Blum W: Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 55:1304–1308. 2014. View Article : Google Scholar : PubMed/NCBI
20	Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, et al: A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 31:1539–1546. 2013. View Article : Google Scholar : PubMed/NCBI
21	Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, Sposto R, van der Giessen J, Eckroth E and Bostrom BC: Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 55:254–259. 2010. View Article : Google Scholar : PubMed/NCBI
22	Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, Liu Y, Feng TT, Meng FY, Liu XL, Jiang QL, et al: Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One. 4:e62572009. View Article : Google Scholar : PubMed/NCBI
23	Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ and Zhao WL: The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia. 23:1507–1514. 2009. View Article : Google Scholar : PubMed/NCBI
24	Hui KF, Leung YY, Yeung PL, Middeldorp JM and Chiang AK: Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines. Br J Haematol. 167:639–650. 2014. View Article : Google Scholar : PubMed/NCBI
25	Schimmel KJ, Richel DJ, van den Brink RB and Guchelaar HJ: Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 30:181–191. 2004. View Article : Google Scholar : PubMed/NCBI
26	Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa H, Chiba S and Furukawa Y: Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia. 28:1216–1226. 2014. View Article : Google Scholar : PubMed/NCBI
27	Song IS, Kim HK, Lee SR, Jeong SH, Kim N, Ko KS, Rhee BD and Han J: Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells. Int J Cancer. 133:1357–1367. 2013. View Article : Google Scholar : PubMed/NCBI
28	Berges C, Haberstock H, Fuchs D, Sadeghi M, Opelz G, Daniel V and Naujokat C: Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4⁺ T cells. J Cell Biochem. 108:935–946. 2009. View Article : Google Scholar : PubMed/NCBI
29	Grandjenette C, Schnekenburger M, Karius T, Ghelfi J, Gaigneaux A, Henry E, Dicato M and Diederich M: 5-aza-2′-deoxycytidine-mediated c-myc down-regulation triggers telomere-dependent senescence by regulating human telomerase reverse transcriptase in chronic myeloid leukemia. Neoplasia. 16:511–528. 2014. View Article : Google Scholar : PubMed/NCBI
30	Voortman J, Checinska A, Giaccone G, Rodriguez JA and Kruyt FA: Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Mol Cancer Ther. 6:1046–1053. 2007. View Article : Google Scholar : PubMed/NCBI
31	Kroemer G, Galluzzi L and Brenner C: Mitochondrial membrane permeabilization in cell death. Physiol Rev. 87:99–163. 2007. View Article : Google Scholar : PubMed/NCBI
32	Akiyama T, Dass CR and Choong PF: Bim-targeted cancer therapy: A link between drug action and underlying molecular changes. Mol Cancer Ther. 8:3173–3180. 2009. View Article : Google Scholar : PubMed/NCBI
33	Wirth M, Stojanovic N, Christian J, Paul MC, Stauber RH, Schmid RM, Häcker G, Krämer OH, Saur D and Schneider G: MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib. Nucleic Acids Res. 42:10433–10447. 2014. View Article : Google Scholar : PubMed/NCBI
34	Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y and Grant S: A Bim-targeting strategy overcomes adaptive bortezomib resistance in multiple myeloma through a novel link between autophagy and apoptosis. Blood. 124:2687–2697. 2014. View Article : Google Scholar : PubMed/NCBI
35	Pigneux A, Mahon FX, Moreau-Gaudry F, Uhalde M, de Verneuil H, Lacombe F, Reiffers J, Milpied N, Praloran V and Belloc F: Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins. Cancer Biol Ther. 6:603–611. 2007. View Article : Google Scholar : PubMed/NCBI
36	Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR and Pollack IF: ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther. 341:859–872. 2012. View Article : Google Scholar : PubMed/NCBI
37	Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM and Fulda S: Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res. 17:4019–4030. 2011. View Article : Google Scholar : PubMed/NCBI